DOTA Zoledronate
Modify Date: 2024-01-11 14:57:08
DOTA Zoledronate structure
|
Common Name | DOTA Zoledronate | ||
|---|---|---|---|---|
| CAS Number | 1908409-18-6 | Molecular Weight | 701.56 | |
| Density | 1.7±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C23H41N7O14P2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of DOTA ZoledronateDOTA Zoledronate is a next-generation agent for bone targeted radionuclide therapy for diagnosing bone metastases[1]. |
| Name | 2,2',2''-{10-[2-({2-[1-(2-Hydroxy-2,2-diphosphonoethyl)-1H-imidazol-4-yl]ethyl}amino)-2-oxoethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triyl}triacetic acid |
|---|---|
| Synonym | More Synonyms |
| Description | DOTA Zoledronate is a next-generation agent for bone targeted radionuclide therapy for diagnosing bone metastases[1]. |
|---|---|
| Related Catalog | |
| In Vitro | DOTA-Zoledronate is a promising agent for the development of other future-oriented radionuclide therapy concepts for personalized nuclear oncology[1]. |
| References |
[1]. The ITM Group Announces In-Licensing of DOTA-Zoledronate Theranostic Agent. |
| Density | 1.7±0.1 g/cm3 |
|---|---|
| Molecular Formula | C23H41N7O14P2 |
| Molecular Weight | 701.56 |
| Exact Mass | 701.218689 |
| LogP | -3.89 |
| Index of Refraction | 1.670 |
| 2,2',2''-{10-[2-({2-[1-(2-Hydroxy-2,2-diphosphonoethyl)-1H-imidazol-4-yl]ethyl}amino)-2-oxoethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triyl}triacetic acid |
| 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[2-[1-(2-hydroxy-2,2-diphosphonoethyl)-1H-imidazol-4-yl]ethyl]amino]-2-oxoethyl]- |